Contero Therapeutics (AgeTech UK) ^NeuroTech

MS, atypical ADT inhibitors. The Contero Management Team has decades of experience in CNS drug discovery, early development and commercialisation. The team has a track record of innovation and delivery, gained across a number of large & mid-size pharmaceutical companies as well as multiple small biotechs. Contero operates a virtual R&D model, working with some of the best CRO and academic groups globally.